TEM - Tempus AI, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $68.14 DETAILS

Stock News

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global H

Sep 04, 2026 05:00 AM • gurufocus.com

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of t.

Sep 04, 2026 04:30 AM • businesswire.com

Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

Sep 02, 2026 08:04 AM • etftrends.com

Tempus AI Director Nadja West Sells 3,000 Shares for $207,000

The disposition involved 3,000 shares executed at $69.00 per share, totaling $207,000 in transaction value on August 28, 2026. The shares traded were equal to 9.00% of the stake held before the filing, leaving the insider with a 0.0183% ownership interest.

Sep 02, 2026 04:35 AM • fool.com

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Sep 01, 2026 08:25 AM • benzinga.com

Piper Sandler Lifts Tempus AI to Overweight at $76

Tempus AI (TEM) rose 2.46% premarket after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $76 from $56. The firm had

Sep 01, 2026 04:45 AM • gurufocus.com

Cathie Wood Invested Roughly $1.4 Billion of Ark Invest's Flagship ETF in Just 3 Artificial Intelligence (AI) Stocks

Wood is known for being a tech-first investor.

Aug 28, 2026 12:45 AM • fool.com

Top Performing Leveraged/Inverse ETFs: 08/23/2026

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

Aug 26, 2026 12:33 PM • etftrends.com

What's Going On With Tempus AI Stock on Monday?

Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.

Aug 24, 2026 10:02 AM • benzinga.com

Best-Performing Leveraged ETF Areas of Last Week

These leveraged ETFs surged last week as biotech, AI, crypto and Bitcoin-linked stocks rallied despite rising Treasury yields.

Aug 24, 2026 05:01 AM • zacks.com

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus' growing cardiovascular portfolio, expanding the company's suite of next-generation AI products aimed at ide.

Aug 24, 2026 04:30 AM • businesswire.com

Why Tempus AI Skyrocketed This Week

Tempus AI stock surged this week after Merck and Moderna published encouraging trial results for a cancer treatment. A company that Tempus AI is acquiring provided technologies that aided the development of Merck and Moderna's cancer vaccine.

Aug 23, 2026 03:15 AM • fool.com

Tempus AI: Winning With Precision Medicine

Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Recent cancer vaccine developments from Merck and Moderna reinforce the strategic relevance and growth runway for TEM's platform. The company already had strong momentum with higher test ASPs, with the cancer tests a huge bonus.

Aug 22, 2026 06:00 AM • seekingalpha.com

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

The transaction involved 3,000 shares with a value of $161,700 on August 14. The sale reduced West's direct equity position by 8%.

Aug 22, 2026 04:19 AM • fool.com

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

Polovin executed the sale of 30,075 shares between August 18 and August 19, generating approximately $1.5 million in proceeds. The transaction was non-discretionary and performed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

Aug 22, 2026 04:05 AM • fool.com

Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know

These 6,175 shares were disposed of at a weighted average price of $49.61 per share, for a total transaction value of $306,342. The transaction was a "sell to cover" event executed to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

Aug 22, 2026 03:58 AM • fool.com

What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing

The transaction involved 48,842 shares with an estimated value of about $2.7 million. This was a non-discretionary transaction executed to cover tax withholding obligations associated with the vesting of restricted stock units.

Aug 22, 2026 03:51 AM • fool.com

Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened

The transactions involved 17,314 shares at a weighted average price of $53.71 per share, totaling $930,000. The sales were executed directly by Schoenherr and were primarily structured to satisfy tax withholding obligations.

Aug 22, 2026 03:40 AM • fool.com

Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter.

The transaction involved 41,095 shares executed at a weighted average price of $49.61 per share, representing a total value of $2.0 million. The sale was non-discretionary, executed to cover tax obligations associated with the vesting of restricted stock units, and does not reflect the insider's view on the stock.

Aug 22, 2026 03:34 AM • fool.com

Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know

The disposition of 133,000 shares was executed at a weighted average price of $49.61 per share, representing a total transaction value of about $6.6 million. The activity was non-discretionary, performed solely to satisfy statutory tax withholding obligations associated with the vesting of restricted stock units.

Aug 22, 2026 02:43 AM • fool.com